Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
ln Vitro |
Nuclear modification of Luc and GFP mRNA with N1-methyl-pseudouridine improves the translation initiation step, partly through blocking eIF2α phosphorylation. In HEK293T cells, mRNA modified by inserting N1-methyl-pseudouridine produced the same amount of luc as standard Luc mRNA. Reduced formation elongation also led to increased polyribosomes and proliferation on Luc mRNA with NN1-methyl-pseudouridine. When Luc and GFP mRNA have access to N1-methyl-pseudouridine, translation is greatly improved in all external translation systems. Luc mRNA is not as crucial as N1-methyl-pseudouridine-Luc mRNA when it comes to polyribosomes [1].
|
---|---|
ln Vivo |
In mice and cell lines, N1-methylpseudouridine-incorporated mRNA combined with pseudouridine-incorporated mRNA can efficiently increase protein expression and decrease immunogenicity [2]. In vivo, m5C/N1-methyl-pseudouridine-modified mRNA is more potent than Ψ and m5C/Ψ-modified mRNA, as is the case with N1-methyl-pseudouridine (1-Mmethylpseudouridine) (20 μg; Im or id route 21 days). high proficiency in translation[2].
|
Animal Protocol |
Animal/Disease Models: 7weeks old balb/c (Bagg ALBino) mouse [1]
Doses: 20 μg Route of Administration: intramuscularor injection route, lasting for 21 days Experimental Results: It has high translation ability. |
References |
[1]. Svitkin YV, et al. N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density. Nucleic Acids Res. 2017 Jun 2;45(10):6023-6036.
[2]. Andries O, et al. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release. 2015 Nov 10;217:337-44. [3]. Nance KD, Meier JL. Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines. ACS Cent Sci. 2021;7(5):748-756. |
Molecular Formula |
C₁₀H₁₄N₂O₆
|
---|---|
Molecular Weight |
258.23
|
Exact Mass |
258.09
|
Elemental Analysis |
C, 46.51; H, 5.46; N, 10.85; O, 37.17
|
CAS # |
13860-38-3
|
Related CAS # |
N1-Methylpseudouridine-5′-triphosphate trisodium;N1-Methylpseudouridine-5′-triphosphate;1428903-59-6;N1-Methylpseudouridine-d3
|
Appearance |
Powder
|
SMILES |
CN1C=C(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O
|
InChi Key |
UVBYMVOUBXYSFV-XUTVFYLZSA-N
|
InChi Code |
InChI=1S/C10H14N2O6/c1-12-2-4(9(16)11-10(12)17)8-7(15)6(14)5(3-13)18-8/h2,5-8,13-15H,3H2,1H3,(H,11,16,17)/t5-,6-,7-,8+/m1/s1
|
Chemical Name |
5-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1-methylpyrimidine-2,4-dione
|
Synonyms |
N1Methylpseudouridine; N1 Methylpseudouridine
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~125 mg/mL (~484.1 mM)
H2O: ~50 mg/mL (~193.6 mM |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.05 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (8.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 50 mg/mL (193.63 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.8725 mL | 19.3626 mL | 38.7252 mL | |
5 mM | 0.7745 mL | 3.8725 mL | 7.7450 mL | |
10 mM | 0.3873 mL | 1.9363 mL | 3.8725 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.